12:25 PM EDT, 05/15/2025 (MT Newswires) -- Eli Lilly ( LLY ) has signed a global research and licensing deal with South Korea-based Rznomics to develop RNA-editing therapies, Rznomics said in a statement Thursday.

The partnership will use Rznomics' proprietary ribozyme platform to target treatments for sensorineural hearing loss.

Rznomics will lead early-stage research, while Lilly will handle later-stage development and global commercialization.

The total deal value could exceed $1.3 billion if all options are exercised, along with future royalties on sales. The upfront payment was not disclosed, according to the company.

Shares of Eli Lilly ( LLY ) were up nearly 2% in recent trading.

Price: 729.33, Change: +13.77, Percent Change: +1.92